RxSight, Inc. 8-K/A

What Happened
RxSight, Inc. filed a Form 8-K/A (filed March 19, 2026) to amend a prior 8-K (filed January 12, 2026) reporting the appointment of Mark Wilterding as Chief Financial Officer. The amendment discloses the previously undetermined sign‑on bonus amount for Mr. Wilterding and corrects the vesting schedule for the stock option granted to him.

Key Details

• Mr. Wilterding’s employment letter was dated December 15, 2025 and became effective January 11, 2026.
• Sign‑on bonus: $169,348.10, determined March 10, 2026 and paid March 13, 2026 (less payroll deductions/withholdings).
• Option vesting: 25% of shares vest on the one‑year anniversary of January 11, 2026; remaining shares vest equally each month over the following three years (fully vested four years from January 11, 2026), subject to continued employment and the applicable option agreement.
• This 8-K/A only amends the Initial Report to add the above compensation details and correct the vesting schedule.

Why It Matters
This filing gives investors the missing compensation specifics for RxSight’s new CFO, clarifying cash and equity obligations tied to his hire. The disclosed sign‑on bonus and four‑year equity vesting are standard executive compensation items; they may affect near‑term payroll expense and long‑term potential dilution from option exercises, but the company did not report any other changes to prior disclosures.